News & Insights Search

A new initiative from the US Food and Drug Administration (FDA) aims to develop “an optimized, fit-for-purpose” framework to facilitate the development and marketing of treatments for rare diseases, according to a 14 October announcement from the agency.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Congress should enact a specific regulatory framework for artificial intelligence (AI) models developed and used in academic medical centers, Scott Gottlieb argued in an opinion piece published in JAMA Health Forum. Such systems should not be regulated as commercial medical devices or left unregulated, according to Gottlieb, a former Commissioner of Food and Drugs, now at the American Enterprise Institute. Three experts who spoke with Focus said they support the plan.

In January, the European Medicines Agency (EMA) will make permanent a pilot project that helps sponsors prepare clinical trial applications.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has adopted a multi-year strategy aimed at ensuring continued patient-centered regulation in the era of emerging artificial intelligence (AI) and personalized medicine. The plan outlines commitments and steps the agency should take through 2030 to keep pace with rapid technological and scientific developments and bring safe and effective treatments to patients more quickly.

Stakeholders are urging the US Food and Drug Administration (FDA) to be flexible in how it regulates psychedelic drugs that may help treat conditions such as major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The agency should be careful not to create unnecessary barriers to patient access, promote proper training and credentialing, and allow flexibility in updating labeling as additional knowledge becomes available, according to individuals and groups that commented via a public docket.

Broader adoption of cloud-based platforms by regulatory bodies could lead to significantly faster approval times, according to a study authored by Nina Cauchon of Amgen and colleagues published in the Journal of Pharmaceutical Sciences.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

The number of clinical trials authorized in the EU and European Economic Area (EEA) has decreased by 13.5% from pre-pandemic levels as Asia has captured a growing share of clinical research.

The US Food and Drug Administration (FDA) last week finalized its guidance on postapproval manufacturing changes for biosimilars to better align with international guidelines and to better address manufacturing changes for interchangeable products, which were not addressed by earlier guidance.